Methods and compositions for treating gastro-esophageal reflux disease
CA 2338465 A1 · Owner: Sepracor, Inc. · Inventors: Jerussi, Thomas P.; Mccullough, John R.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compositions employing and methods utilizing the optically pure (+) isomer of norcisapride are disclosed. This compound has surprisingly been found to be a potent drug for the treatment of disorders of the central nervous system. The compound, (+) norcisapride, has also been found to be a potent antiemetic agent. Finally, the (+) isomer of norcisapride also avoids certain adverse side effects and certain adverse drug interactions. The compound is further useful for treating gastro-intestinal motility dysfunction gastro-esophageal , reflux disease, dyspepsia gastroparesis, intestinal pseudo-obstruction. It has a prokinetic effect.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 23, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 23, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 23, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.